-
-
-
-
-
-
-
Mizuho on Verastem (VSTM): 'we continue to favor it as a top small cap biotech idea'
-
-
-
-
-
-
-
Verastem Oncology (VSTM) Outlines 2025 Strategic Priorities and Milestones for Novel Pipeline Targeting RAS/MAPK Pathway-Driven Cancers
-
-
-
-
-
-
-
Verastem Oncology Announces FDA Acceptance and Priority Review of New Drug Application for Avutometinib in Combination with Defactinib for the Treatment of Recurrent KRAS Mutant Low-Grade Serous Ovari
-
-
-
-
14,982 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

